Ob jective:To investigate the clinical efficacy and immune function of salmeterol fluticasone joint with montelukast on asthmatic children .Method:From January 2011 to December 2013, 102 cases of asthmatic children were divided into test group and control group according to different treatment methods , each had 51 cases.The control group accepted salmeterol fluticasone inhalants ,while the test group accepted montelukast on the basis of control group .Result:The total effective rate of test group was 96.1%,while the control group was 82.4%,the difference was statistically significant ( P <0.05) .The difference was not statis-tically significant on compliance rates of lung function between the two groups before the treatment ( P>0.05) . But at he treatment of 3 months and after 3 months,the compliance rates of lung function of text group were all better than the control group ( P<0.05) .The difference was not statistically significant on IL-4,INF-γ, n IgE,EOS between the two groups before the treatment (P>0.05).But at he treatment of 3 months and after 3 months,the levels of IL-4,IgE and EOS of two groups were all lower than before ,and the levels of the INF-γwas higher than before ( P<0.05) .The difference was statistically significant between the two groups ( P<0. 05).Con clusion:The treatment of salmeterol fluticasone joint with montelukast on asthmatic children have significant effect , good safety .It is worthy of being popularizing on clinical .%目的：探讨沙美特罗替卡松联合孟鲁斯特治疗支气管哮喘患儿对临床疗效、免疫功能的影响。方法：选取我院自2011年1月至2013年12月收治的哮喘患儿102例，按治疗方法的不同分为试验组及对照组，各51例。对照组患儿给予沙美特罗替卡松粉吸入剂，试验组在此基础上给予口服孟鲁司特钠。观察患儿治疗前后临床疗效及免疫功能的情况。结果：试验组患儿治疗总有效率为96．1％，对照组患儿治疗后总有效率为82．4％，试验组患儿治疗后总有效率显著优于对照组，差异有统计学意义（P＜0．05）。两组患儿治疗前肺功能达标率，差异无统计学意义（P＞0．05）。试验组患儿治疗3个月及治疗后3个月肺功能达标率显著优于对照组患儿，差异有统计学意义（ P＜0．05）。两组患儿治疗前IL－4、INF－γ、IgE、EOS无显著差异，差异无统计学意义（ P＞0．05）。两组患儿治疗3个月及治疗后3个月肺功能IL－4、IgE及EOS水平均较治疗前明显降低，而INF－γ较治疗前明显升高（P＜0．05），试验组患儿治疗3个月及治疗后3个月肺功能IL－4、IgE及EOS水平降低及INF－γ升高有显著差异，差异有统计学意义（ P＜0．05）。结论：应用沙美特罗替卡松联合孟鲁斯特治疗小儿哮喘具有明显疗效，安全性较好，依从性好，值得临床推广。
展开▼
